Remdesivir

COVID-19 Therapy

OTHER NAMES	CLASSIFICATION	ALERTS
Veklury	Antiviral	

PREPARATION and ADMINISTRATION

Authorized by Health Canada under Notice of Compliance with Conditions (NOC/c) for one or all of its intended uses

Reconstitution

Diluent: sterile water for injection

Discard vial if no vacuum present.
100 mg vial – add 19 mL to produce a concentration of 5 mg/mL.
Vial may contain overfill; withdraw exact volume that corresponds to dose; 100 mg = 20 mL, 200 mg = 40 mL.
After drug has been added to bag, invert 20 times to mix. Do not shake.

IV Direct	Intermittent Infusion	Continuous Infusion
Not applicable	**IV Bag (large volume pump)**	**IV Bag (large volume pump)**
	Standard preparation Diluent: NS Remove volume from IV bag equal to the volume of drug being added 100 mg/250 mL total over 30-60 min 200 mg/250 mL total over 30-60 min	Not applicable
	Syringe (syringe pump)	**Syringe (syringe pump)**
	Not applicable	Not applicable
Requirements and Monitoring		
Not applicable	Flush with at least 30 mL NS after completion of the infusion using the same rate of administration (250 mL/h)	Not applicable

INDICATIONS

- Treatment of moderate-severe coronavirus disease 2019 (COVID-19) in hospitalized patients.
- Treatment of symptomatic, non-severe COVID-19 in individuals who are at high risk for progression to severe disease within 7 days of symptom onset.

Remdesivir

COVID-19 Therapy

OTHER NAMES	CLASSIFICATION	ALERTS
Veklury	Antiviral	

ADVERSE EFFECTS

- Increase in transaminases; discontinue if ALT is 5 times the upper limit of normal.
- Nausea, headache.
- Rash, hypersensitivity.
- Infusion-related reaction (rare); decrease rate of infusion.

DOSAGE

- Loading dose: 200 mg IV on day one, followed by 100 mg IV once daily for duration of treatment (usually 3-10 days).
- Dosage adjustment in renal dysfunction not required.
- For ambulatory patient convenience (i.e., to align with other ambulatory visits), consider:

Patient Population	Alternative dosage for "convenience of dosing"
Chronic kidney disease (CKD) including peritoneal dialysis	200 mg IV once, followed by 100 mg IV 48 hours later x 1 dose
CKD including hemodialysis	200 mg IV once, followed by 100 mg IV 48-72 hours later x 1 dose

- Remdesivir should not be initiated in patients with ALT greater than or equal to 5 times the upper limit of normal.

COMPATIBILITY, STABILITY

- Compatible at Y-site with NS.
- Prepare intermittent infusions in concentrations of 0.4-2 mg/mL in NS. Infusion must be completed within 4 h of preparation. In fluid restricted patients, 100 mg or 200 mg can be diluted in 100 mL (1 mg/mL and 2 mg/mL respectively). Administer using Drug X.
- Vial contains no preservative. Discard unused portion.

DOSAGE FORMS

- 100 mg vial.

MISCELLANEOUS

LIBRARIES

- Searchable Drug Library Document

REFERENCES

Trissel LA. Handbook on injectable drugs. Bethesda (MD): American Society of Health-System Pharmacists; 2017.

Remdesivir product monograph. Mississauga (ON): Gilead Sciences Canada Inc; Accessed 2020 August 29